<DOC>
	<DOCNO>NCT02074644</DOCNO>
	<brief_summary>The purpose study determine whether prostatic arterial embolization ( PAE ) compare effective safe treatment benign prostatic hyperplasia patient severe low urinary tract symptom adequately control medical therapy alpha-blocker , assess International Prostate Symptom Score ( IPSS ) 6 month . Patients randomize 1:1 ratio PAE sham procedure evaluate 1 , 3 6 month . Patients randomize sham procedure offer possibility perform PAE 6 month . All patient may participate optional 6-months extension study .</brief_summary>
	<brief_title>Clinical Trial Prostatic Arterial Embolization Versus Sham Procedure Treat Benign Prostatic Hyperplasia</brief_title>
	<detailed_description>This randomize , parallel-group , evaluator-blind , superiority , control clinical trial PAE versus sham procedure patient BPH severe LUTS adequately control medical therapy alpha-blocker . This study screen visit day -14 , baseline visit day -2 , randomization intervention visit day 0 , follow visit month 1 , 3 6 . Patients initially randomize sham procedure complete 6 month follow-up period offer possibility perform PAE cost . All patient invite participate 6 month post-trial extension study . Patients 45 years-old diagnosis BPH associate severe LUTS define IPSS &gt; =20 minimum 6 month treatment alpha-blocker prostate volume ≥ 40 mL start two week screen period . Eligible patient start either tamsulosin 0.4 mg q.d. , alfuzosin 10 mg q.d . silodosin 8 mg q.d. , maintain throughout study period , intervention schedule follow 2 day ( study day 0 ) , randomize PAE sham procedure procedure technically feasible Those patient angiography show PAE technically feasible randomize one study arm 1:1 ratio . Patients group submit exactly procedure , except patient randomize control group inject polyvinyl alcohol particle . Patients discharge soon clinical condition stabilize Patients assess 1 , 3 6 month IPSS , QoL , IIEF , BPH-II perform prostatic ultrasonography , uroflowmetry PSA month 1 6 . At 1 month pelvic NMR perform evaluate prostate volume degree ischemia . Patients complete 6 month follow-up period invite enter 6 month extension study . In extension study , patient evaluate month 12 efficacy variable . Patients initially randomize sham procedure want perform PAE conclusion trial evaluate month 1 , 3 6 PAE .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Prostatic Diseases</mesh_term>
	<mesh_term>Genital Diseases , Male</mesh_term>
	<criteria>Male patient ≥ 45 yearsold Diagnosis BPH base clinical history , digital rectal examination , urine sediment , transrectal prostate ultrasound PSA Use market alphablocker LUTS/BPH previous 6 month Severe low urinary tract symptom screen baseline define follow : IPSS ( 7 item ) ≥ 20 , QoL ≥ 3 , Qmax &lt; 12 mL/s prostate volume ≥ 40 mL CTA show prostatic artery feasible PAE Sexual dysfunction accept risk develop sexual dysfunction treatment Written inform consent Previous surgical invasive prostate treatment TURP , TUMT , TUNA , laser minimally invasive treatment Acute chronic prostatitis suspect prostatitis include chronic pain , intermittent pain abnormal sensation penis , testis , anal pelvic area past 12 month History prostate bladder cancer pelvic irradiation Active recurrent urinary tract infection ( 1 episode last 12 month ) History neurogenic bladder LUTS secondary neurological disease Advanced atherosclerosis tortuosity iliac prostatic artery Secondary renal insufficiency ( due prostatic obstruction ) Large bladder diverticulum stone Detrusor failure Previous history acute urinary retention Current severe , significant uncontrolled disease ( include , limited metabolic , hematologic , renal , hepatic , pulmonary , neurologic , endocrine , cardiac , infectious gastrointestinal , uncontrolled hypertension ( systolic ≥ 160 mmHg and/or diastolic ≥95 mmHg ) , congestive heart failure [ New York Heart Association status class III IV ] , myocardial infarction within 26 week prior randomization ) , judgment clinical investigator render subject unsuitable trial put subject increase risk Any bleeding disorder hemophilia , clot factor deficiency , anticoagulation bleed diathesis Hypersensitivity contraindication tamsulosin use Administration 5ARIs , finasteride dutasteride previous 2 week 4 month , respectively . These patient may include stop medication replace tansulosin , alfuzosin silodosin least 2 week 4 month , respectively . Any mental condition disorder would interfere subject 's ability provide inform consent Participation study investigational drug device previous 3 month</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Prostatism</keyword>
	<keyword>Randomized Controlled Trial</keyword>
	<keyword>Embolization , Therapeutic</keyword>
	<keyword>Hyperplasia</keyword>
	<keyword>Prostatic Diseases</keyword>
	<keyword>Genital Diseases , Male</keyword>
</DOC>